Van Naarden Jacob
SEC CIK 1661254 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LLY | Lilly (Eli) | SVP, CEO LoxoONC, Pres LlyONC | 26.6K | $647.4K | — | 16 | 2022-02-16 | 2026-02-09 |
Most active insiders at LLY, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LILLY ENDOWMENT INC | Former 10% Shareholder | — | $3.34B |
| 2 | Jonsson Patrik | EVP, Pres, LLY Int'l | — | $7.64M |
| 3 | Hakim Anat | EVP, GC, Sec | — | $5.95M |
| 4 | Zakrowski Donald A | SVP, CAO, Fin | — | $3.38M |
| 5 | Yuffa Ilya | EVP, Pres, LLY USA, Gbl Capab | — | $2.88M |
| 6 | Brown Adrienne S | EVP, Pres LLY Imm | — | — |
| 7 | Custer Kenneth L. | EVP, Pres, Card Met Hlth | — | — |
| 8 | Seymour Melissa | EVP, Gbl Quality | — | — |
| 9 | Dozier Eric | EVP, CHRO | — | — |
| 10 | Hernandez Edgardo | EVP, Pres, Mfg. Ops | — | — |
| 14 | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | — | — |
Transactions 16
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-11 | 2026-02-09 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | A - Grant | $1,044.67 | +4,866 | 26.6K | +22% | +$5.08M | |
| D | 2026-02-03 | 2026-02-01 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | F - Tax | $1,037.15 | -1,909 | 22.8K | -8% | -$1.98M |
| D | 2026-02-03 | 2026-02-01 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | M - OptEx | $0.00 | +4,108 | 24.7K | +20% | $0 |
| 2025-08-13 | 2025-08-13 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Lilly Oncology | P - Purchase | $647.36 | +1,000 | 20.6K | +5% | +$647.4K | |
| D | 2025-02-12 | 2025-02-10 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Lilly Oncology | A - Grant | $868.88 | +6,104 | 19.6K | +45% | +$5.30M |
| D | 2025-02-04 | 2025-02-01 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Lilly Oncology | M - OptEx | $0.00 | +3,023 | 14.9K | +26% | $0 |
| D | 2025-02-04 | 2025-02-01 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Lilly Oncology | F - Tax | $811.08 | -1,410 | 13.5K | -9% | -$1.14M |
| 2024-11-01 | 2024-10-31 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Lilly Oncology | G - Gift | $0.00 | -4,302 | 11.8K | -27% | $0 | |
| D | 2024-02-14 | 2024-02-12 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Loxo@Lilly | A - Grant | $737.26 | +2,369 | 16.1K | +17% | +$1.75M |
| D | 2024-02-02 | 2024-02-01 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Loxo@Lilly | F - Tax | $645.61 | -1,685 | 13.8K | -11% | -$1.09M |
| D | 2024-02-02 | 2024-02-01 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, Pres, Loxo@Lilly | M - OptEx | $0.00 | +3,618 | 15.5K | +31% | $0 |
| D | 2023-02-21 | 2023-02-16 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, CEO Loxo@Lilly | M - OptEx | $0.00 | +2,785 | 13.2K | +27% | $0 |
| D | 2023-02-21 | 2023-02-16 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, CEO Loxo@Lilly | F - Tax | $335.01 | -1,314 | 11.8K | -10% | -$440.2K |
| 2023-02-14 | 2023-02-10 | LLY | Lilly (Eli) | Van Naarden Jacob | EVP, CEO Loxo@Lilly | A - Grant | $345.12 | +2,407 | 10.4K | +30% | +$830.7K | |
| D | 2022-02-17 | 2022-02-16 | LLY | Lilly (Eli) | Van Naarden Jacob | SVP, CEO LoxoONC, Pres LlyONC | F - Tax | $243.84 | -2,186 | 7,967 | -22% | -$533.0K |
| D | 2022-02-17 | 2022-02-16 | LLY | Lilly (Eli) | Van Naarden Jacob | SVP, CEO LoxoONC, Pres LlyONC | M - OptEx | $0.00 | +5,461 | 10.2K | +116% | $0 |
Purchase Sale Sale after option exercise All abbreviations